Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-CAR039 in Relapsed/Refractory B-NHL
NCT04696432Phase 1Completed
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Nov 2020
- Primary completion
- Jul 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of prizloncabtagene autoleucel in B-cell non-Hodgkin lymphoma, sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Adverse Events at 24 months. Started Nov 2020; status: completed.
02
Drugs
prizloncabtagene autoleucel
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04696432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04696432.